Pentostatin in chronic lymphocytic leukemia Journal Article


Authors: Sauter, C.; Lamanna, N.; Weiss, M. A.
Article Title: Pentostatin in chronic lymphocytic leukemia
Abstract: Background: Chronic lymphocytic leukemia (CLL) is a disease that typically afflicts older individuals with a median age of diagnosis in the eighth decade of life for which treatments available now are not curative. Although purine analogue based combinations produce complete responses (CRs) in many patients, the use of these combinations has been limited by toxicity including myelosuppression and an increased risk of infectious complications. Objective: To identify the role of pentostatin, a specific inhibitor of adenosine deaminase (ADA), in the treatment of CLL. We compare pentostatin to other purine analogues, most notably fludarabine, with regard to safety and efficacy. Finally, we review the use of pentostatin in other diseases. Methods: The scope of this review encompasses the history of treatment for CLL as well as the genesis of modern combination chemoimmunotherapy and the advantages of pentostatin within such a treatment program. Results: Combination therapy with pentostatin seems to provide response frequencies comparable to fluclarabine based combinations but with less toxicity and with greater ease of administration. © 2008 Informa UK Ltd.
Keywords: treatment response; aged; fludarabine; prednisone; clinical trial; neutropenia; review; dose response; drug dose reduction; drug efficacy; drug safety; monotherapy; unspecified side effect; antineoplastic agents; clinical trials as topic; disease free survival; rituximab; cancer immunotherapy; infection; multiple cycle treatment; pharmacodynamics; anemia; bone marrow suppression; nausea; thrombocytopenia; antineoplastic combined chemotherapy protocols; combination chemotherapy; cyclophosphamide; drug structure; cutaneous t cell lymphoma; drug mechanism; lymphatic leukemia; drug half life; corticosteroid; immunosuppressive treatment; chronic lymphatic leukemia; drug excretion; leukemia, lymphocytic, chronic, b-cell; alemtuzumab; chlorambucil; pentostatin; vidarabine; drug formulation; cladribine; drug elimination; hairy cell leukemia; chronic lymphocytic leukemia; t cell prolymphocytic leukemia; adenosine deaminase
Journal Title: Expert Opinion on Drug Metabolism and Toxicology
Volume: 4
Issue: 9
ISSN: 1742-5255
Publisher: Informa Healthcare  
Date Published: 2008-09-01
Start Page: 1217
End Page: 1222
Language: English
DOI: 10.1517/17425255.4.9.1217
PUBMED: 18721115
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 3" - "Export Date: 17 November 2011" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Nicole Lamanna
    57 Lamanna
  2. Craig Steven Sauter
    158 Sauter
  3. Mark Weiss
    80 Weiss